Status:
COMPLETED
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Small Cell
Eligibility:
All Genders
Brief Summary
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
Detailed Description
To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with ...
Eligibility Criteria
Inclusion
- Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.
Exclusion
- Patients who have no treatment history with the product (i.e.,durvalumab)
Key Trial Info
Start Date :
April 22 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 25 2023
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT04854590
Start Date
April 22 2021
End Date
July 25 2023
Last Update
July 24 2024
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chiba, Japan
2
Research Site
Fukuoka, Japan
3
Research Site
Gunma, Japan
4
Research Site
Hokkaido, Japan